Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN LABEL, PROSPECTIVE, POST MARKETING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF RITUXIMAB WITH GLUCOCORTICOIDS IN ADULT PATIENTS WITH WEGENER'S GRANULOMATOSIS (GRANULOMATOSIS WITH POLYANGIITIS - GPA) OR MICROSCOPIC POLYANGIITIS

Trial Profile

AN OPEN LABEL, PROSPECTIVE, POST MARKETING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF RITUXIMAB WITH GLUCOCORTICOIDS IN ADULT PATIENTS WITH WEGENER'S GRANULOMATOSIS (GRANULOMATOSIS WITH POLYANGIITIS - GPA) OR MICROSCOPIC POLYANGIITIS

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Methylprednisolone; Prednisolone; Prednisone
  • Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Oct 2019 Planned End Date changed from 30 Jun 2021 to 19 Aug 2020.
    • 07 Oct 2019 Planned primary completion date changed from 30 Jun 2021 to 19 Aug 2020.
    • 29 Mar 2019 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top